Each year, approximately 1.6 million patients are treated with Stallergenes Greer medicines. Stallergenes Greer is firmly focused on innovation, and thanks to unique expertise in its knowledge of allergens, the Company makes a major contribution to the development of allergy immunotherapy, offering allergy sufferers a comprehensive range of increasingly effective solutions tailored to their needs.
As of 2003, the company has started an ambitious clinical development program which consists of developing a new generation of allergen immunotherapy products: pharmaceutical specialties covering allergens that trigger 80% of respiratory allergies worldwide.
Stallergenes Greer is also exploring the possibilities to extend allergy immunotherapy use to other allergic diseases than just respiratory allergies. Notably through collaborations, Stallergenes Greer is continuing to invest to make AIT treatments accessible to more allergy patients through even less invasive routes and facilitating access to allergen immunotherapy for other impacting allergic diseases such as food allergies.